레노보RxRNXT 주가

RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer

The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used

RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting

Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common

[4] 내부자 거래 — 4

[10-K/A] 10-K/A — 10-K/A

RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript

RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.

RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.

RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.

RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™...

Earnings Scheduled For May 14, 2026

[10-Q] 분기 실적 — 10-Q